David G. Alleva

2.7k total citations
33 papers, 1.8k citations indexed

About

David G. Alleva is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, David G. Alleva has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in David G. Alleva's work include Immune Cell Function and Interaction (9 papers), Immune cells in cancer (9 papers) and Chemokine receptors and signaling (7 papers). David G. Alleva is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Immune cells in cancer (9 papers) and Chemokine receptors and signaling (7 papers). David G. Alleva collaborates with scholars based in United States, Mexico and Canada. David G. Alleva's co-authors include Klaus D. Elgert, David W. Mullins, Carol J. Burger, D I Beller, Paul Conlon, K D Elgert, Paul D. Crowe, Eric B. Johnson, Stefen A. Boehme and Francisco M. Lio and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

David G. Alleva

33 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David G. Alleva United States 21 1.0k 435 431 400 276 33 1.8k
Judith Agudo United States 28 645 0.6× 320 0.7× 718 1.7× 474 1.2× 368 1.3× 48 2.1k
T Tamaya Japan 29 379 0.4× 469 1.1× 835 1.9× 353 0.9× 158 0.6× 155 2.3k
Hun Sik Kim South Korea 24 1.8k 1.8× 276 0.6× 573 1.3× 792 2.0× 289 1.0× 55 2.8k
Yasunori Kadowaki Japan 24 582 0.6× 251 0.6× 575 1.3× 245 0.6× 509 1.8× 32 1.6k
W Northemann Germany 18 436 0.4× 241 0.6× 614 1.4× 257 0.6× 224 0.8× 32 1.5k
Sarah Kraus Israel 19 382 0.4× 402 0.9× 642 1.5× 344 0.9× 89 0.3× 69 1.6k
Marcia Meseck United States 24 691 0.7× 571 1.3× 1.1k 2.5× 640 1.6× 693 2.5× 41 2.5k
Lorenza Ronfani Italy 11 750 0.7× 235 0.5× 811 1.9× 152 0.4× 90 0.3× 12 1.8k
Alois Palmetshofer Germany 21 996 1.0× 131 0.3× 793 1.8× 217 0.5× 273 1.0× 32 2.1k
Vicki M. Eng Switzerland 8 706 0.7× 353 0.8× 317 0.7× 263 0.7× 81 0.3× 8 1.6k

Countries citing papers authored by David G. Alleva

Since Specialization
Citations

This map shows the geographic impact of David G. Alleva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Alleva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Alleva more than expected).

Fields of papers citing papers by David G. Alleva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Alleva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Alleva. The network helps show where David G. Alleva may publish in the future.

Co-authorship network of co-authors of David G. Alleva

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Alleva. A scholar is included among the top collaborators of David G. Alleva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Alleva. David G. Alleva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alleva, David G., Sylaja Murikipudi, T. Lancaster, et al.. (2024). An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes. Frontiers in Immunology. 15. 1367514–1367514. 6 indexed citations
2.
3.
Lu, Hang, Mili Gu, Janet L. Lathey, et al.. (2013). Characterization of the Native Form of Anthrax Lethal Factor for Use in the Toxin Neutralization Assay. Clinical and Vaccine Immunology. 20(7). 986–997. 2 indexed citations
4.
Villegas, Sonia L., Yujin Huang, Clarence Ahlem, et al.. (2010). Amelioration of Glucose Intolerance by the Synthetic Androstene HE3286: Link to Inflammatory Pathways. Journal of Pharmacology and Experimental Therapeutics. 333(1). 70–80. 25 indexed citations
5.
Hevezi, Peter, et al.. (2008). Gene Array Analysis Comparison between Rat Collagen‐induced Arthritis and Human Rheumatoid Arthritis. Scandinavian Journal of Immunology. 68(1). 43–57. 20 indexed citations
6.
Maki, R., Peter Hevezi, Gail Verge, et al.. (2006). Experimental Autoimmune Encephalomyelitis Develops in CC Chemokine Receptor 7‐deficient Mice with Altered T‐cell Responses. Scandinavian Journal of Immunology. 64(4). 361–369. 22 indexed citations
7.
Ott, Thomas, Anil Pahuja, Sarah A. Nickolls, David G. Alleva, & R. Scott Struthers. (2004). Identification of CC Chemokine Receptor 7 Residues Important for Receptor Activation. Journal of Biological Chemistry. 279(41). 42383–42392. 21 indexed citations
8.
Ott, Thomas, Anil Pahuja, Francisco M. Lio, et al.. (2004). A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells. Journal of Pharmacological and Toxicological Methods. 51(2). 105–114. 11 indexed citations
9.
Maki, Richard A., Weidong Yang, David Schwarz, et al.. (2003). Cutting Edge: Diabetes-Associated Quantitative Trait Locus, Idd4 , Is Responsible for the IL-12p40 Overexpression Defect in Nonobese Diabetic (NOD) Mice. The Journal of Immunology. 171(7). 3333–3337. 26 indexed citations
10.
Antel, Jack P., et al.. (2002). Persistence of Immune Responses to Altered and Native Myelin Antigens in Patients with Multiple Sclerosis Treated with Altered Peptide Ligand. Clinical Immunology. 104(2). 105–114. 40 indexed citations
11.
Alleva, David G., Eric B. Johnson, Francisco M. Lio, et al.. (2002). Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma.. PubMed. 71(4). 677–85. 110 indexed citations
12.
Alleva, David G., Paul D. Crowe, Liping Jin, et al.. (2001). A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. Journal of Clinical Investigation. 107(2). 173–180. 179 indexed citations
13.
14.
Alleva, David G., et al.. (1997). Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice. The Journal of Immunology. 159(11). 5610–5619. 44 indexed citations
15.
16.
Alleva, David G., David S. Askew, Carol J. Burger, & Klaus D. Elgert. (1994). Macrophage Priming and Activation During Fibrosarcoma Growth: Expression of c-myb, c-myc, c-fos, and c-fms. Immunological Investigations. 23(6-7). 457–472. 4 indexed citations
17.
Alleva, David G., Carol J. Burger, & K D Elgert. (1994). Tumour Growth Causes Suppression of Autoreactive T‐Cell Proliferation by Disrupting Macrophage Responsiveness to Interferon‐γ. Scandinavian Journal of Immunology. 39(1). 31–38. 22 indexed citations
18.
Alleva, David G., Carol J. Burger, & K D Elgert. (1994). Tumor-induced regulation of suppressor macrophage nitric oxide and TNF- alpha production. Role of tumor-derived IL-10, TGF- beta , and prostaglandin E2.. The Journal of Immunology. 153(4). 1674–1686. 201 indexed citations
19.
Alleva, David G.. (1994). Regulation of macrophage activities by tumor growth: mechanisms of immunosuppression. VTechWorks (Virginia Tech). 1 indexed citations
20.
Alleva, David G., Carol J. Burger, & Klaus D. Elgert. (1993). Tumor-Induced Macrophage Tumor Necrosis Factor-α Production Suppresses Autoreactive T Cell Proliferation. Immunobiology. 188(4-5). 430–445. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judith Agudo Breakdown of academic impact, for papers by T Tamaya Breakdown of academic impact, for papers by Hun Sik Kim Breakdown of academic impact, for papers by Yasunori Kadowaki Breakdown of academic impact, for papers by W Northemann Breakdown of academic impact, for papers by Sarah Kraus Breakdown of academic impact, for papers by Marcia Meseck Breakdown of academic impact, for papers by Lorenza Ronfani Breakdown of academic impact, for papers by Alois Palmetshofer Breakdown of academic impact, for papers by Vicki M. Eng
Rankless by CCL
2026